Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2016-05-01
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Oral cancer tumor cells produce biochemical substances, tumor markers, differed from healthy individuals in expression or quantitative ratio, detectable in tissues and/or body fluids.
Saliva, because of its accessibility, proximity and noninvasive approach, presents an ideal tool for the research of oral cancer tumor markers.
The aim of this study will be to isolate, quantify, analyze the role and describe the kinetics of diadenosine tetraphosphate (Ap4A), Squamous Cell Carcinoma associated Antigen (SCCA), Trophoblast cell surface antigen (TROP2) in patients with OC, potentially malignant disorders (PMOD) and age and sex matched control group with a clear medical history.
There are number of studies published on OC tumor markers isolated mostly in serum, however the satisfactory specificity and sensitivity still hasn't been reached.
Liquid chromatography-ion trap-mass spectrometry, Multiple Reaction Monitoring method (LC-IT-MS, MRM) will be developed to isolate and quantify the above mentioned tumor markers. This method has not yet been used to quantify the above mentioned salivary tumor markers. Ap4A and TROP2 have never been isolated from saliva.
The aim is to develop a tumor-specific test with a satisfactory statistical sensitivity and specificity and dynamically measure the levels of tumor markers, before and immediately after therapy - surgery/radiotherapy/chemotherapy or their combination, and during regular follow-up one and two years after surgery. As another novelty, the investigators aim to determine the markers circadian rhythm.
A OC tumor specific test, with satisfactory sensitivity and specificity, would enable earlier OC diagnosis, possibly before the clinical appearance, raise the survival rate of OC patients, enable early diagnosis of recurrence and/or new primary tumors and ensure better post-treatment life-quality.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of Salivary Proteomic Biomarkers for Early Detection of Oral Cancer in Egyptian Population
NCT06471270
Salivary Cytokines as Biomarker for Oral Health
NCT02807519
Innovative Approach to Triage Oral Precancer
NCT03202810
Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression
NCT01531881
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
NCT06031337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OC is preceded by a preinvasive stage, which may last for many years. Tumor progression in epithelia has been classified as normal, hyperplastic (non-dysplastic), dysplastic carcinoma in situ and invasive carcinoma. The majority of the initial alterations of precancerous and cancerous oral lesions are often non recognizable, even by histopathological examination. The basic biology of initiation and progression of these tumors is still obscure. Carcinogenesis is a process which includes initiation, promotion and progression, driven by accumulation of specific altered genes. Tumor cells produce biochemical substances called tumor markers. Some of these substances found in healthy individuals, but with altered quantitative ratio. Besides the salivary DNA and RNA, other markers are detectable in saliva, such as cell cycle markers (p53, p16 etc.), growth factors (EGF, TGF, etc.), cell surface markers, oxidants and antioxidants and other. Because of its accessibility, non-invasive approach and location proximity, saliva presents an ideal tool for the research of OC tumor markers.
This study will analyze the role of Diadenosine tetraphosphate (Ap4A), Squamous Cell Carcinoma associated Antigen 1 and 2 (SCCA1 and 2) and Trophoblast Cell Surface Antigen (TROP2) in the development of OC.
Ap4A is the only diadenosine polyphosphate that can induce a considerable increase in \[Ca2+\] in endothelial cells, indicating that its vasoactive effects are comparable to the known effects of arginine vasopressin, angiotensin II and adenosine triphosphate (ATP). Ap4A is a ubiquitous diadenosine polyphosphate signal molecule for DNA replication in mammalian cell.
Level of Ap4A was found to be directly related to the proliferative activity of the cells. It is considered that the Ap4A has an important role in the regulation of cellular growth and division. In the absence of the tumor suppressor gene FHIT (Fragile Histidine Triad), located on the chromosome 3p, Ap4a accumulates and leads to DNA synthesis and multiplication of cells. Loss of heterozygosity of the chromosome 3p is believed to be a common event in the early phase of carcinogenesis.
Ap4A could represent a tumor marker for the early stages of carcinogenesis. Possibly it could indicate carcinogenesis earlier than pathohistological diagnostics. Ap4a has never been isolated in saliva or measured in OC and PMOD patients.
In healthy individuals, SCCA, a glycoprotein, is located inside the cell. In individuals with OC it is released from the cell and thereby, is detectable in serum and saliva. Recent reports have shown that SCCA can influence the invasion or metastasis of cancer cells. However, it remains unclear how SCCA acts to mediate these biological functions. SCCA has already been presented as a potential serum marker for pathologic lymph node metastasis, advanced tumor stage, and an increased rate of distant metastasis in patients with OC, however, never has it been isolated in saliva in OC patients. It has never been measured in patients with PMOD.
The human trophoblast cell-surface antigen, TROP2 (also termed GA733-1, M1S1, EGP-1) is encoded by the TACSTD2 gene, which is mapped to the human chromosome 1p32. TROP2 function and role is still not well understood, although it has previously been suggested that it played a role in growth regulation of cancer cells, as well as in fetal lung formation as a calcium signal transducer. Two studies showed that TROP2 over-expression may emerge as a prognostic tool in patients with oral and laryngeal squamous cell carcinoma. TROP2 antigen has never been isolated or measured in saliva in OC and PMOD patients. OC tumor-specific test will probably have to involve two or all of the above described tumor markers. However, salivary Ap4a alone could present a marker for the earliest stages of OC carcinogenesis. Therefore, it could reveal carcinogenesis before the clinical appearance of OC. The investigators believe that saliva proximity to OC could enable even higher specificity. As another novelty, determining the circadian rhythm of the above mentioned markers should provide more information on their kinetics and role in OC carcinogenesis and rule out any potential confounders, such as the influence of a certain nutritive or the influence of some habits e.g. smoking.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Cancer group
Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
Saliva sampling
Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
ELISA
Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
HPLC
High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
PMOD group
Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
Saliva sampling
Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
ELISA
Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
HPLC
High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
Control
Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
Saliva sampling
Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
ELISA
Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
HPLC
High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saliva sampling
Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
ELISA
Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
HPLC
High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinically diagnosed leukoplakia, erythroplakia and oral lichen planus
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Croatian Science Foundation
OTHER_GOV
University of Zagreb
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Darko Macan
Professor, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darko Macan, PhD, DDS
Role: PRINCIPAL_INVESTIGATOR
University of Zagreb
Related Links
Access external resources that provide additional context or updates about the study.
OFFICIAL PROJECT PAGE
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRZZ IP-09-2014-9376
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.